Stockscreener 앱 받기
12.12
3.11%
0.375
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option - Stock Titan
[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options - Stock Titan
Director at Corvus (CRVS) receives grant of 15,000 stock options - Stock Titan
Corvus (CRVS) director awarded options for 15,000 shares at $11.60 - Stock Titan
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest - Yahoo Finance
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Insider Monkey
Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes - Stock Titan
Corvus Hikes on Position in Angel - Baystreet.ca
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China - The Manila Times
$13.5M bet on soquelitinib: China eczema and asthma trials move ahead - Stock Titan
Corvus Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
CRVS: Soquelitinib progresses in pivotal trials for PTCL and AD, targeting broad immunology markets - TradingView
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Corvus drops after early-stage trial data for eczema therapy - MSN
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness - Sahm
Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Biotech Corvus heads to Jefferies and Goldman Sachs health conferences - Stock Titan
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst CallSlideshow (NASDAQ:CRVS) 2026-05-18 - Seeking Alpha
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase - sharewise.com
Boxer Capital Management's New Stake in Corvus Pharmaceuticals: SEC Filing DetailsNews and Statistics - IndexBox
Corvus Pharmaceuticals, Inc.Common Stock (NQ: CRVS - FinancialContent
Point72, Steven A. Cohen show 0% stake in Corvus (CRVS) - Stock Titan
A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40 - Moomoo
Sirenia/Alex Silverstein disclose 6.83M warrant shares for Corvus (NASDAQ: CRVS) - Stock Titan
Corvus Pharmaceuticals : CRVS SID Investor Meeting Presentation FINAL - marketscreener.com
Corvus Pharmaceuticals Reports Positive Final Phase 1 Results for Soquelitinib in Atopic Dermatitis at SID 2026 Annual Meeting 16 - Minichart
Corvus drops on trial data for eczema therapy (CRVS:NASDAQ) - Seeking Alpha
Corvus Pharmaceuticals Down Over 11%, On Track for Largest Percent Decrease Since March 2025 -- Data Talk - Moomoo
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting - markets.businessinsider.com
Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results - TipRanks
Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety - TradingView
Corvus (Nasdaq: CRVS) details Phase 1 soquelitinib eczema results and next trials - Stock Titan
Drug-free remissions seen after short atopic dermatitis treatment - Stock Titan
Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40 - Moomoo
CRVS PE Ratio & Valuation, Is CRVS Overvalued - Intellectia AI
TradingKey - TradingKey
Number of shareholders of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Number of shareholders of Corvus Pharmaceuticals, Inc. – TRADEGATE:C17 - TradingView
Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS - Sahm
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS) - Yahoo Finance
Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33 - Moomoo
MSN Money - MSN
Corvus: Q1 Earnings Snapshot - theheraldreview.com
Corvus Pharmaceuticals earnings up next as AD trial looms By Investing.com - Investing.com Australia
Corvus Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
6.83%
0.11%
자본화:
|
볼륨(24시간):